Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy.
Al-Zaidy S, Pickard AS, Kotha K, Alfano LN, Lowes L, Paul G, Church K, Lehman K, Sproule DM, Dabbous O, Maru B, Berry K, Arnold WD, Kissel JT, Mendell JR, Shell R. Al-Zaidy S, et al. Among authors: maru b. Pediatr Pulmonol. 2019 Feb;54(2):179-185. doi: 10.1002/ppul.24203. Epub 2018 Dec 12. Pediatr Pulmonol. 2019. PMID: 30548438 Free PMC article. Clinical Trial.
Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8.
Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM. Dabbous O, et al. Among authors: maru b. Adv Ther. 2019 Nov;36(11):2982-2985. doi: 10.1007/s12325-019-01088-0. Epub 2019 Sep 11. Adv Ther. 2019. PMID: 31512141 Free PMC article. No abstract available.
An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER).
Dean R, Jensen I, Cyr P, Miller B, Maru B, Sproule DM, Feltner DE, Wiesner T, Malone DC, Bischof M, Toro W, Dabbous O. Dean R, et al. Among authors: maru b. J Mark Access Health Policy. 2021 Feb 28;9(1):1889841. doi: 10.1080/20016689.2021.1889841. J Mark Access Health Policy. 2021. PMID: 33708361 Free PMC article.
Severe communication delays are independent of seizure burden and persist despite contemporary treatments in SCN1A+ Dravet syndrome: Insights from the ENVISION natural history study.
Perry MS, Scheffer IE, Sullivan J, Brunklaus A, Boronat S, Wheless JW, Laux L, Patel AD, Roberts CM, Dlugos D, Holder D, Knupp KG, Lallas M, Phillips S, Segal E, Smeyers P, Lal D, Wirrell E, Zuberi S, Brünger T, Wojnaroski M, Maru B, O'Donnell P, Morton M, James E, Vila MC, Huang N, Gofshteyn JS, Rico S. Perry MS, et al. Among authors: maru b. Epilepsia. 2024 Feb;65(2):322-337. doi: 10.1111/epi.17850. Epub 2023 Dec 22. Epilepsia. 2024. PMID: 38049202 Free article.
PARP-1 improves leukemia outcomes by inducing parthanatos during chemotherapy.
Maru B, Messikommer A, Huang L, Seipel K, Kovecses O, Valk PJM, Theocharides APA, Mercier FE, Pabst T, McKeague M, Luedtke NW. Maru B, et al. Cell Rep Med. 2023 Sep 19;4(9):101191. doi: 10.1016/j.xcrm.2023.101191. Epub 2023 Sep 7. Cell Rep Med. 2023. PMID: 37683650 Free PMC article.
Enhancing CAR-T Cell Therapy with Functional Nucleic Acids.
Maru B, Nadeau L, McKeague M. Maru B, et al. ACS Pharmacol Transl Sci. 2021 Nov 17;4(6):1716-1727. doi: 10.1021/acsptsci.1c00188. eCollection 2021 Dec 10. ACS Pharmacol Transl Sci. 2021. PMID: 34927006 Free PMC article. Review.
23 results